What? When? Why?

Latest Happenings in Business World

Share on

Dec-2021

Antibody Production Market Size To Grow USD 22.28 Bn By 2026

North America led the global antibody production market in 2020.

As per our research report, the global antibody production market size is forecasted to be worth USD 22.28 billion by 2026 and showcase a CAGR of 14.44% from 2021 to 2026.

Throughout 2020, the COVID-19 pandemic has had a significant impact on noncommunicable disease care worldwide, severely affecting the healthcare field. While many branches of medicine have adapted to these sudden restrictions and lockdowns, there is increased demand for various antibodies to treat diseases. Widespread infection of COVID-19 has increased the number of people suffering from acute/chronic diseases. In addition, there is a higher risk of infection and associated co-morbidities in older people and young children. Therefore, many people were terrified of getting infected, and people resorted to bulk purchases from the black market to avoid unnecessary hospitalization and visits. These factors are expected to accelerate the growth of the global antibody production market during the forecast period.

Targeted therapy is gaining importance because of its specificity against target antigens while avoiding toxicity for non-target cells. In addition, as the prevalence of infections increases, antibodies are receiving more and more attention. According to the American Cancer Society estimates, 1,735,400 new cancer cases and 609,650 cancer deaths were diagnosed in the United States in 2019. Some monoclonal antibodies used in targeted therapies are bevacizumab, cetuximab, and ipilimumab.

In developed and developing nations, there is a higher approval rate of therapeutic antibodies by regulatory agencies and increased R&D spending by pharmaceutical and biotechnology companies; this is helping to drive the market. In addition, the impending expiration of many high-performing monoclonal antibody patents is expected to favor the market's growth.

With continuous R&D, there is an increasing number of clinical trials that play a key role in the manufacture and launch of antibodies. The success rates and strategic concepts of biologics have also led large pharmaceutical companies to shift their interest toward precision medicine. Over the past two decades, the chimerization and humanization of monoclonal antibodies have led to the approval of various drugs and therapies to treat autoimmune diseases, cancer transplant rejection, etc. All these factors drive the antibody production market during the forecast period.

However, the production costs of antibodies and strict government regulations are anticipated to hamper the market's growth. In addition, the lengthy time taken to launch a product is very long, deviating from the focus of market players to save resources; this is further estimated to challenge the growth of the global antibody production market.

KEY MARKET INSIGHTS:

Based on antibody type, the monoclonal antibody segment is anticipated to grow at a CAGR of 13.55% over the forecast period. Increasing demand for the treatment of chronic diseases, including blood disorders, cancer, and growth hormone deficiency, among others, are a few of the notable factors accelerating the segment's growth during the forecast period.
Based on end-user, the pharmaceuticals and biotechnology companies segment is anticipated to be the dominant segment among allowing the massive production of therapeutic antibodies and the high investment in R&D by companies for the improvement of drugs. The research institutes segment expects a healthy CAGR during the forecast period. The growth of the research institutes segment is expected to be driven by a large number of drug development procedures with significant investments from key players.
Based on the region, the North American region is anticipated to account for the majority of the share in the global market during the forecast period. The antibody production market in the United States is projected to reach over USD 4.86 billion by 2026. Factors responsible for this regional growth are the growing incidence of cancer, the growing geriatric population, government funding for medical research in the United States, the need for quality cancer treatment, and regulatory approvals and authorizations for rapid launches of mAbs in Canada. Meanwhile, the APAC region will have the highest growth during the projected period. The Chinese regional market will reach a projected USD 5.68 billion by 2026, with an annual compound rate of 16.16%, during the forecast period. Over the forecast period, Japan, Germany, and Canada are forecasted to grow at around 8.77%, 9.81%, and 10.46%, respectively.
A few significant players dominate the studied market. However, it is anticipated to grow due to the collaborations and partnerships between pharmaceutical and biotechnology companies to develop advanced monoclonal antibodies. Some of the major players in the global antibody production market profiled in this report are GE Healthcare (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), Pall Corporation (U.S.), Sigma-Aldrich Corporation (Germany), Eppendorf AG (Germany), Cellab GmbH (Germany), INTEGRA Biosciences AG (Switzerland) and FiberCell Systems Inc. (United States).

MARKET SEGMENTATION:

By Type: